Immunocore focuses on the development of immunotherapeutic drugs for the treatment of cancer, and infectious diseases. The company develops drugs using proprietary T cell receptor (TCR) technology. Immunocore launched KIMMTRAK® (tebentafusp-tebn) in 2021 for metastatic uveal melanoma. Immunocore listed on NASDAQ in 2021.